Review




Structured Review

Procell Inc mb49 cells
Drug release and tumor-killing effects of MR@BCG. (A) The loading capacity and encapsulation efficiency of PTX under different coating concentrations. (B) The release of free PTX from MRs over time in urine and PBS. (C) The tumor-killing effects of MR and PTX on bladder cancer <t>MB49</t> cells. (D) Propidium iodide (PI) staining of MB49 cells treated with PBS, bare MRs, PTX, and MRs with PTX, respectively. Scale bar: 200 μm.(E to H) Expression of maturation markers of CD4 + , CD8 + , CD86 + , and CD206 + after 7 d of incubation with MR@BCG or control samples. (I to L) Concentrations of tumor necrosis factor-α (TNF-α), interferon-γ (IFN-γ), interleukin-2 (IL-2), and interleukin-6 (IL-6) after incubation with MR@BCG or control samples for 48 h.
Mb49 Cells, supplied by Procell Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mb49+cells/pmc13121890-41-0-5?v=Procell+Inc
Average 86 stars, based on 1 article reviews
mb49 cells - by Bioz Stars, 2026-07
86/100 stars

Images

1) Product Images from "Hybrid-Driven Bacillus Calmette–Guérin Carrier for Targeted Immuno-Chemo Combo Therapy in Bladder Cancer"

Article Title: Hybrid-Driven Bacillus Calmette–Guérin Carrier for Targeted Immuno-Chemo Combo Therapy in Bladder Cancer

Journal: Cyborg and Bionic Systems

doi: 10.34133/cbsystems.0492

Drug release and tumor-killing effects of MR@BCG. (A) The loading capacity and encapsulation efficiency of PTX under different coating concentrations. (B) The release of free PTX from MRs over time in urine and PBS. (C) The tumor-killing effects of MR and PTX on bladder cancer MB49 cells. (D) Propidium iodide (PI) staining of MB49 cells treated with PBS, bare MRs, PTX, and MRs with PTX, respectively. Scale bar: 200 μm.(E to H) Expression of maturation markers of CD4 + , CD8 + , CD86 + , and CD206 + after 7 d of incubation with MR@BCG or control samples. (I to L) Concentrations of tumor necrosis factor-α (TNF-α), interferon-γ (IFN-γ), interleukin-2 (IL-2), and interleukin-6 (IL-6) after incubation with MR@BCG or control samples for 48 h.
Figure Legend Snippet: Drug release and tumor-killing effects of MR@BCG. (A) The loading capacity and encapsulation efficiency of PTX under different coating concentrations. (B) The release of free PTX from MRs over time in urine and PBS. (C) The tumor-killing effects of MR and PTX on bladder cancer MB49 cells. (D) Propidium iodide (PI) staining of MB49 cells treated with PBS, bare MRs, PTX, and MRs with PTX, respectively. Scale bar: 200 μm.(E to H) Expression of maturation markers of CD4 + , CD8 + , CD86 + , and CD206 + after 7 d of incubation with MR@BCG or control samples. (I to L) Concentrations of tumor necrosis factor-α (TNF-α), interferon-γ (IFN-γ), interleukin-2 (IL-2), and interleukin-6 (IL-6) after incubation with MR@BCG or control samples for 48 h.

Techniques Used: Encapsulation, Staining, Expressing, Incubation, Control

In vivo therapeutic efficacy of MR@BCG against bladder cancer. (A) Schematic of the study protocol in establishing orthotopic MB49 bladder tumors in C57BL/6 mice, followed by various intravesical administrations. (B) Representative in vivo bioluminescence images and (C) bioluminescence intensity of MB49-tumor-bearing mice under various intravesical administrations over the treatment course. (D) Survival rate and (E) body weight of mice under various intravesical administrations over the treatment course. (F to I) Concentrations of TNF-α, IFN-γ, IL-2, and IL-6 in bladder tissues after treatment with MR@BCG or control samples. (J) Immunofluorescence images showing CD8 + and CD86 + cells. Scale bar: 70 μm (K) Hematoxylin and eosin (H&E) staining images of bladder tissue. Scale bar: 125 μm. DAPI, 4′,6-diamidino-2-phenylindole.
Figure Legend Snippet: In vivo therapeutic efficacy of MR@BCG against bladder cancer. (A) Schematic of the study protocol in establishing orthotopic MB49 bladder tumors in C57BL/6 mice, followed by various intravesical administrations. (B) Representative in vivo bioluminescence images and (C) bioluminescence intensity of MB49-tumor-bearing mice under various intravesical administrations over the treatment course. (D) Survival rate and (E) body weight of mice under various intravesical administrations over the treatment course. (F to I) Concentrations of TNF-α, IFN-γ, IL-2, and IL-6 in bladder tissues after treatment with MR@BCG or control samples. (J) Immunofluorescence images showing CD8 + and CD86 + cells. Scale bar: 70 μm (K) Hematoxylin and eosin (H&E) staining images of bladder tissue. Scale bar: 125 μm. DAPI, 4′,6-diamidino-2-phenylindole.

Techniques Used: In Vivo, Drug discovery, Control, Immunofluorescence, Staining



Similar Products

99
CancerTools Org mb49
Mb49, supplied by CancerTools Org, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mb49+cells/cancertools+org___153368?v=CancerTools+Org
Average 99 stars, based on 1 article reviews
mb49 - by Bioz Stars, 2026-07
99/100 stars
  Buy from Supplier

86
Purdue University Cytometry murine bladder cancer cell line mb49
Combination of T-mfIL12 with immature BMDCs or iPSDCs in the subcutaneous <t>MB49</t> tumor model (A) Combination of T-mfIL12 with immature BMDCs in the subcutaneous MB49 tumor model. A marked inhibition of tumor growth was observed in the T-mfIL12+BMDC group. Significant tumor growth inhibitions compared to the mock group were also seen in the T-01+BMDC and T-mfIL12 monotherapy groups. n = 6 mice per group. Error bars represent standard error of the mean (SEM). ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. (B) Combination of T-mfIL12 with immature iPSDCs in the subcutaneous MB49 tumor model. A significant inhibition of tumor growth was observed in the T-mfIL12+iPSDC group, which was comparable to the inhibition seen in the T-mfIL12+BMDC group. n = 6 mice per group. Error bars represent SEM. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001.
Murine Bladder Cancer Cell Line Mb49, supplied by Purdue University Cytometry, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mb49+cells/pmc13273829-138-1-19?v=Purdue+University+Cytometry
Average 86 stars, based on 1 article reviews
murine bladder cancer cell line mb49 - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier

86
Procell Inc mb49 cells
Drug release and tumor-killing effects of MR@BCG. (A) The loading capacity and encapsulation efficiency of PTX under different coating concentrations. (B) The release of free PTX from MRs over time in urine and PBS. (C) The tumor-killing effects of MR and PTX on bladder cancer <t>MB49</t> cells. (D) Propidium iodide (PI) staining of MB49 cells treated with PBS, bare MRs, PTX, and MRs with PTX, respectively. Scale bar: 200 μm.(E to H) Expression of maturation markers of CD4 + , CD8 + , CD86 + , and CD206 + after 7 d of incubation with MR@BCG or control samples. (I to L) Concentrations of tumor necrosis factor-α (TNF-α), interferon-γ (IFN-γ), interleukin-2 (IL-2), and interleukin-6 (IL-6) after incubation with MR@BCG or control samples for 48 h.
Mb49 Cells, supplied by Procell Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mb49+cells/pmc13121890-41-0-5?v=Procell+Inc
Average 86 stars, based on 1 article reviews
mb49 cells - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier

86
Procell Inc mouse bladder carcinoma cell line mb49
Drug release and tumor-killing effects of MR@BCG. (A) The loading capacity and encapsulation efficiency of PTX under different coating concentrations. (B) The release of free PTX from MRs over time in urine and PBS. (C) The tumor-killing effects of MR and PTX on bladder cancer <t>MB49</t> cells. (D) Propidium iodide (PI) staining of MB49 cells treated with PBS, bare MRs, PTX, and MRs with PTX, respectively. Scale bar: 200 μm.(E to H) Expression of maturation markers of CD4 + , CD8 + , CD86 + , and CD206 + after 7 d of incubation with MR@BCG or control samples. (I to L) Concentrations of tumor necrosis factor-α (TNF-α), interferon-γ (IFN-γ), interleukin-2 (IL-2), and interleukin-6 (IL-6) after incubation with MR@BCG or control samples for 48 h.
Mouse Bladder Carcinoma Cell Line Mb49, supplied by Procell Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mb49+cells/pm41950100-359-1-10?v=Procell+Inc
Average 86 stars, based on 1 article reviews
mouse bladder carcinoma cell line mb49 - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier

93
AcceGen Biotechnology mb49 mouse bca cells
Drug release and tumor-killing effects of MR@BCG. (A) The loading capacity and encapsulation efficiency of PTX under different coating concentrations. (B) The release of free PTX from MRs over time in urine and PBS. (C) The tumor-killing effects of MR and PTX on bladder cancer <t>MB49</t> cells. (D) Propidium iodide (PI) staining of MB49 cells treated with PBS, bare MRs, PTX, and MRs with PTX, respectively. Scale bar: 200 μm.(E to H) Expression of maturation markers of CD4 + , CD8 + , CD86 + , and CD206 + after 7 d of incubation with MR@BCG or control samples. (I to L) Concentrations of tumor necrosis factor-α (TNF-α), interferon-γ (IFN-γ), interleukin-2 (IL-2), and interleukin-6 (IL-6) after incubation with MR@BCG or control samples for 48 h.
Mb49 Mouse Bca Cells, supplied by AcceGen Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mb49+cells/pm41898771-177-0-7?v=AcceGen+Biotechnology
Average 93 stars, based on 1 article reviews
mb49 mouse bca cells - by Bioz Stars, 2026-07
93/100 stars
  Buy from Supplier

86
Merck & Co murine bladder cancer cell line mb49
Drug release and tumor-killing effects of MR@BCG. (A) The loading capacity and encapsulation efficiency of PTX under different coating concentrations. (B) The release of free PTX from MRs over time in urine and PBS. (C) The tumor-killing effects of MR and PTX on bladder cancer <t>MB49</t> cells. (D) Propidium iodide (PI) staining of MB49 cells treated with PBS, bare MRs, PTX, and MRs with PTX, respectively. Scale bar: 200 μm.(E to H) Expression of maturation markers of CD4 + , CD8 + , CD86 + , and CD206 + after 7 d of incubation with MR@BCG or control samples. (I to L) Concentrations of tumor necrosis factor-α (TNF-α), interferon-γ (IFN-γ), interleukin-2 (IL-2), and interleukin-6 (IL-6) after incubation with MR@BCG or control samples for 48 h.
Murine Bladder Cancer Cell Line Mb49, supplied by Merck & Co, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mb49+cells/pm41826511-771-1-10?v=Merck+%26+Co
Average 86 stars, based on 1 article reviews
murine bladder cancer cell line mb49 - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier

86
Merck & Co x 106 mb49 bladder tumor cells
Drug release and tumor-killing effects of MR@BCG. (A) The loading capacity and encapsulation efficiency of PTX under different coating concentrations. (B) The release of free PTX from MRs over time in urine and PBS. (C) The tumor-killing effects of MR and PTX on bladder cancer <t>MB49</t> cells. (D) Propidium iodide (PI) staining of MB49 cells treated with PBS, bare MRs, PTX, and MRs with PTX, respectively. Scale bar: 200 μm.(E to H) Expression of maturation markers of CD4 + , CD8 + , CD86 + , and CD206 + after 7 d of incubation with MR@BCG or control samples. (I to L) Concentrations of tumor necrosis factor-α (TNF-α), interferon-γ (IFN-γ), interleukin-2 (IL-2), and interleukin-6 (IL-6) after incubation with MR@BCG or control samples for 48 h.
X 106 Mb49 Bladder Tumor Cells, supplied by Merck & Co, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mb49+cells/pm41723132-353-20-26?v=Merck+%26+Co
Average 86 stars, based on 1 article reviews
x 106 mb49 bladder tumor cells - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier

86
Procell Inc murine bca cell line mb49
MCUB promoted PD‐L1 expression and tumor progression in BCa. A) IHC staining images of MCUB and PD‐L1 in 10 BCa samples. B) Correlation analysis between MCUB and PD‐L1 IHC scores. C) Western blotting of PD‐L1 expression in MCUB knockdown (shMCUB) and overexpression (oeMCUB) UMUC3 cells. D) Representative tumor images and tumor weights from xenograft models following MCUB knockdown or overexpression in <t>MB49</t> cells ( N = 6 per group). E) IHC staining images of PD‐L1 in subcutaneous tumors at 20× and 40× magnifications. Statistical analysis was performed using Student's t ‐test. * p <0.05, ** p <0.01, *** p <0.001.
Murine Bca Cell Line Mb49, supplied by Procell Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mb49+cells/pmc12849890-231-1-11?v=Procell+Inc
Average 86 stars, based on 1 article reviews
murine bca cell line mb49 - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier

86
Jackson Laboratory mb49 cells
MCUB promoted PD‐L1 expression and tumor progression in BCa. A) IHC staining images of MCUB and PD‐L1 in 10 BCa samples. B) Correlation analysis between MCUB and PD‐L1 IHC scores. C) Western blotting of PD‐L1 expression in MCUB knockdown (shMCUB) and overexpression (oeMCUB) UMUC3 cells. D) Representative tumor images and tumor weights from xenograft models following MCUB knockdown or overexpression in <t>MB49</t> cells ( N = 6 per group). E) IHC staining images of PD‐L1 in subcutaneous tumors at 20× and 40× magnifications. Statistical analysis was performed using Student's t ‐test. * p <0.05, ** p <0.01, *** p <0.001.
Mb49 Cells, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mb49+cells/pmc12849890-263-0-27?v=Jackson+Laboratory
Average 86 stars, based on 1 article reviews
mb49 cells - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier

Image Search Results


Combination of T-mfIL12 with immature BMDCs or iPSDCs in the subcutaneous MB49 tumor model (A) Combination of T-mfIL12 with immature BMDCs in the subcutaneous MB49 tumor model. A marked inhibition of tumor growth was observed in the T-mfIL12+BMDC group. Significant tumor growth inhibitions compared to the mock group were also seen in the T-01+BMDC and T-mfIL12 monotherapy groups. n = 6 mice per group. Error bars represent standard error of the mean (SEM). ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. (B) Combination of T-mfIL12 with immature iPSDCs in the subcutaneous MB49 tumor model. A significant inhibition of tumor growth was observed in the T-mfIL12+iPSDC group, which was comparable to the inhibition seen in the T-mfIL12+BMDC group. n = 6 mice per group. Error bars represent SEM. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001.

Journal: Molecular Therapy Oncology

Article Title: Induced pluripotent stem cell-derived dendritic cells potentiate the efficacy of interleukin-12-expressing oncolytic HSV-1

doi: 10.1016/j.omton.2026.201252

Figure Lengend Snippet: Combination of T-mfIL12 with immature BMDCs or iPSDCs in the subcutaneous MB49 tumor model (A) Combination of T-mfIL12 with immature BMDCs in the subcutaneous MB49 tumor model. A marked inhibition of tumor growth was observed in the T-mfIL12+BMDC group. Significant tumor growth inhibitions compared to the mock group were also seen in the T-01+BMDC and T-mfIL12 monotherapy groups. n = 6 mice per group. Error bars represent standard error of the mean (SEM). ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. (B) Combination of T-mfIL12 with immature iPSDCs in the subcutaneous MB49 tumor model. A significant inhibition of tumor growth was observed in the T-mfIL12+iPSDC group, which was comparable to the inhibition seen in the T-mfIL12+BMDC group. n = 6 mice per group. Error bars represent SEM. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001.

Article Snippet: The murine bladder cancer cell line MB49, originally induced by 7,12-dimethylbenz[a]anthracene, was kindly provided by Dr. Timothy L. Ratliff (Purdue University, USA; RRID: CVCL_7076).

Techniques: Inhibition

Immunological assessments of the combination of T-mfIL12 and immature BMDCs (A) Immunohistochemical analysis of representative MB49 tumors from the indicated treatment groups. Increased intratumoral infiltration of CD8 + lymphocytes was most prominent in the T-mfIL12+BMDC group, followed by the T-01+BMDC group. In both groups, elevated levels of CD4 + lymphocyte infiltration were also observed in the same tumor sections. Other groups, except for the mock group, showed moderate levels of CD4 + infiltration. Scale bars: 100 μm. (B) ELISpot assay for IFN-γ expression revealed the highest number of IFN-γ-producing splenocytes in the T-mfIL12+BMDC group, followed by the T-01+BMDC group. Monotherapies with BMDC, T-01, or T-mfIL12, as well as the mock group, did not result in significant increases. n = 3 per group; all samples were analyzed in triplicate. Error bars represent standard deviation (SD). ∗ p < 0.05, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001.

Journal: Molecular Therapy Oncology

Article Title: Induced pluripotent stem cell-derived dendritic cells potentiate the efficacy of interleukin-12-expressing oncolytic HSV-1

doi: 10.1016/j.omton.2026.201252

Figure Lengend Snippet: Immunological assessments of the combination of T-mfIL12 and immature BMDCs (A) Immunohistochemical analysis of representative MB49 tumors from the indicated treatment groups. Increased intratumoral infiltration of CD8 + lymphocytes was most prominent in the T-mfIL12+BMDC group, followed by the T-01+BMDC group. In both groups, elevated levels of CD4 + lymphocyte infiltration were also observed in the same tumor sections. Other groups, except for the mock group, showed moderate levels of CD4 + infiltration. Scale bars: 100 μm. (B) ELISpot assay for IFN-γ expression revealed the highest number of IFN-γ-producing splenocytes in the T-mfIL12+BMDC group, followed by the T-01+BMDC group. Monotherapies with BMDC, T-01, or T-mfIL12, as well as the mock group, did not result in significant increases. n = 3 per group; all samples were analyzed in triplicate. Error bars represent standard deviation (SD). ∗ p < 0.05, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001.

Article Snippet: The murine bladder cancer cell line MB49, originally induced by 7,12-dimethylbenz[a]anthracene, was kindly provided by Dr. Timothy L. Ratliff (Purdue University, USA; RRID: CVCL_7076).

Techniques: Immunohistochemical staining, Enzyme-linked Immunospot, Expressing, Standard Deviation

Immunological assessments of the combination of T-mfIL12 and immature iPSDCs (A) Immunohistochemical analysis of representative MB49 tumors from the indicated treatment groups. Increased intratumoral infiltration of CD8 + lymphocytes was observed in both the T-mfIL12+BMDC and T-mfIL12+iPSDC groups. In both groups, CD4 + lymphocyte infiltration was also more prominently observed in the same tumor sections. Other treatment groups, excluding the mock group, exhibited moderate levels of CD4 + T cell infiltration. Scale bars: 100 μm. (B) ELISpot assay showed a high and comparable increase in IFN-γ-producing splenocytes in both the T-mfIL12+BMDC and T-mfIL12+iPSDC groups. n = 3 mice per group; all samples were analyzed in triplicate. Error bars represent standard deviation (SD). ∗∗∗∗ p < 0.0001; NS, not significant.

Journal: Molecular Therapy Oncology

Article Title: Induced pluripotent stem cell-derived dendritic cells potentiate the efficacy of interleukin-12-expressing oncolytic HSV-1

doi: 10.1016/j.omton.2026.201252

Figure Lengend Snippet: Immunological assessments of the combination of T-mfIL12 and immature iPSDCs (A) Immunohistochemical analysis of representative MB49 tumors from the indicated treatment groups. Increased intratumoral infiltration of CD8 + lymphocytes was observed in both the T-mfIL12+BMDC and T-mfIL12+iPSDC groups. In both groups, CD4 + lymphocyte infiltration was also more prominently observed in the same tumor sections. Other treatment groups, excluding the mock group, exhibited moderate levels of CD4 + T cell infiltration. Scale bars: 100 μm. (B) ELISpot assay showed a high and comparable increase in IFN-γ-producing splenocytes in both the T-mfIL12+BMDC and T-mfIL12+iPSDC groups. n = 3 mice per group; all samples were analyzed in triplicate. Error bars represent standard deviation (SD). ∗∗∗∗ p < 0.0001; NS, not significant.

Article Snippet: The murine bladder cancer cell line MB49, originally induced by 7,12-dimethylbenz[a]anthracene, was kindly provided by Dr. Timothy L. Ratliff (Purdue University, USA; RRID: CVCL_7076).

Techniques: Immunohistochemical staining, Enzyme-linked Immunospot, Standard Deviation

Immunohistochemical analysis of DC surface markers in MB49 tumors Representative tumor sections were stained for CD11c (a marker of DC presence) and CD86 (a marker of DC maturation). Tumors from the BMDC and iPSDC monotherapy groups were CD11c-positive but CD86-negative, indicating the presence of immature DCs. In contrast, tumors from the T-mfIL12+BMDC and T-mfIL12+iPSDC groups were positive for both CD11c and CD86, suggesting the presence of mature DCs. Tumors from the mock and T-mfIL12 monotherapy groups were negative for both markers. These findings suggest that the co-administration of T-mfIL12 may promote DC maturation in the tumor microenvironment. Scale bars: 100 μm.

Journal: Molecular Therapy Oncology

Article Title: Induced pluripotent stem cell-derived dendritic cells potentiate the efficacy of interleukin-12-expressing oncolytic HSV-1

doi: 10.1016/j.omton.2026.201252

Figure Lengend Snippet: Immunohistochemical analysis of DC surface markers in MB49 tumors Representative tumor sections were stained for CD11c (a marker of DC presence) and CD86 (a marker of DC maturation). Tumors from the BMDC and iPSDC monotherapy groups were CD11c-positive but CD86-negative, indicating the presence of immature DCs. In contrast, tumors from the T-mfIL12+BMDC and T-mfIL12+iPSDC groups were positive for both CD11c and CD86, suggesting the presence of mature DCs. Tumors from the mock and T-mfIL12 monotherapy groups were negative for both markers. These findings suggest that the co-administration of T-mfIL12 may promote DC maturation in the tumor microenvironment. Scale bars: 100 μm.

Article Snippet: The murine bladder cancer cell line MB49, originally induced by 7,12-dimethylbenz[a]anthracene, was kindly provided by Dr. Timothy L. Ratliff (Purdue University, USA; RRID: CVCL_7076).

Techniques: Immunohistochemical staining, Staining, Marker

Drug release and tumor-killing effects of MR@BCG. (A) The loading capacity and encapsulation efficiency of PTX under different coating concentrations. (B) The release of free PTX from MRs over time in urine and PBS. (C) The tumor-killing effects of MR and PTX on bladder cancer MB49 cells. (D) Propidium iodide (PI) staining of MB49 cells treated with PBS, bare MRs, PTX, and MRs with PTX, respectively. Scale bar: 200 μm.(E to H) Expression of maturation markers of CD4 + , CD8 + , CD86 + , and CD206 + after 7 d of incubation with MR@BCG or control samples. (I to L) Concentrations of tumor necrosis factor-α (TNF-α), interferon-γ (IFN-γ), interleukin-2 (IL-2), and interleukin-6 (IL-6) after incubation with MR@BCG or control samples for 48 h.

Journal: Cyborg and Bionic Systems

Article Title: Hybrid-Driven Bacillus Calmette–Guérin Carrier for Targeted Immuno-Chemo Combo Therapy in Bladder Cancer

doi: 10.34133/cbsystems.0492

Figure Lengend Snippet: Drug release and tumor-killing effects of MR@BCG. (A) The loading capacity and encapsulation efficiency of PTX under different coating concentrations. (B) The release of free PTX from MRs over time in urine and PBS. (C) The tumor-killing effects of MR and PTX on bladder cancer MB49 cells. (D) Propidium iodide (PI) staining of MB49 cells treated with PBS, bare MRs, PTX, and MRs with PTX, respectively. Scale bar: 200 μm.(E to H) Expression of maturation markers of CD4 + , CD8 + , CD86 + , and CD206 + after 7 d of incubation with MR@BCG or control samples. (I to L) Concentrations of tumor necrosis factor-α (TNF-α), interferon-γ (IFN-γ), interleukin-2 (IL-2), and interleukin-6 (IL-6) after incubation with MR@BCG or control samples for 48 h.

Article Snippet: MB49 cells were purchased from Procell.

Techniques: Encapsulation, Staining, Expressing, Incubation, Control

In vivo therapeutic efficacy of MR@BCG against bladder cancer. (A) Schematic of the study protocol in establishing orthotopic MB49 bladder tumors in C57BL/6 mice, followed by various intravesical administrations. (B) Representative in vivo bioluminescence images and (C) bioluminescence intensity of MB49-tumor-bearing mice under various intravesical administrations over the treatment course. (D) Survival rate and (E) body weight of mice under various intravesical administrations over the treatment course. (F to I) Concentrations of TNF-α, IFN-γ, IL-2, and IL-6 in bladder tissues after treatment with MR@BCG or control samples. (J) Immunofluorescence images showing CD8 + and CD86 + cells. Scale bar: 70 μm (K) Hematoxylin and eosin (H&E) staining images of bladder tissue. Scale bar: 125 μm. DAPI, 4′,6-diamidino-2-phenylindole.

Journal: Cyborg and Bionic Systems

Article Title: Hybrid-Driven Bacillus Calmette–Guérin Carrier for Targeted Immuno-Chemo Combo Therapy in Bladder Cancer

doi: 10.34133/cbsystems.0492

Figure Lengend Snippet: In vivo therapeutic efficacy of MR@BCG against bladder cancer. (A) Schematic of the study protocol in establishing orthotopic MB49 bladder tumors in C57BL/6 mice, followed by various intravesical administrations. (B) Representative in vivo bioluminescence images and (C) bioluminescence intensity of MB49-tumor-bearing mice under various intravesical administrations over the treatment course. (D) Survival rate and (E) body weight of mice under various intravesical administrations over the treatment course. (F to I) Concentrations of TNF-α, IFN-γ, IL-2, and IL-6 in bladder tissues after treatment with MR@BCG or control samples. (J) Immunofluorescence images showing CD8 + and CD86 + cells. Scale bar: 70 μm (K) Hematoxylin and eosin (H&E) staining images of bladder tissue. Scale bar: 125 μm. DAPI, 4′,6-diamidino-2-phenylindole.

Article Snippet: MB49 cells were purchased from Procell.

Techniques: In Vivo, Drug discovery, Control, Immunofluorescence, Staining

MCUB promoted PD‐L1 expression and tumor progression in BCa. A) IHC staining images of MCUB and PD‐L1 in 10 BCa samples. B) Correlation analysis between MCUB and PD‐L1 IHC scores. C) Western blotting of PD‐L1 expression in MCUB knockdown (shMCUB) and overexpression (oeMCUB) UMUC3 cells. D) Representative tumor images and tumor weights from xenograft models following MCUB knockdown or overexpression in MB49 cells ( N = 6 per group). E) IHC staining images of PD‐L1 in subcutaneous tumors at 20× and 40× magnifications. Statistical analysis was performed using Student's t ‐test. * p <0.05, ** p <0.01, *** p <0.001.

Journal: Advanced Science

Article Title: MCUB Inhibits PRKN‐Dependent Mitophagic Degradation of PD‐L1 to Promote Immune Evasion in Bladder Cancer

doi: 10.1002/advs.202514764

Figure Lengend Snippet: MCUB promoted PD‐L1 expression and tumor progression in BCa. A) IHC staining images of MCUB and PD‐L1 in 10 BCa samples. B) Correlation analysis between MCUB and PD‐L1 IHC scores. C) Western blotting of PD‐L1 expression in MCUB knockdown (shMCUB) and overexpression (oeMCUB) UMUC3 cells. D) Representative tumor images and tumor weights from xenograft models following MCUB knockdown or overexpression in MB49 cells ( N = 6 per group). E) IHC staining images of PD‐L1 in subcutaneous tumors at 20× and 40× magnifications. Statistical analysis was performed using Student's t ‐test. * p <0.05, ** p <0.01, *** p <0.001.

Article Snippet: The murine BCa cell line MB49 (RRID: CVCL_7076) was obtained from Procell Life Science & Technology Co., Ltd (Wuhan, China) with catalogue number CL‐0733.

Techniques: Expressing, Immunohistochemistry, Western Blot, Knockdown, Over Expression

MCUB promoted PD‐L1 expression and tumor progression in BCa. A) IHC staining images of MCUB and PD‐L1 in 10 BCa samples. B) Correlation analysis between MCUB and PD‐L1 IHC scores. C) Western blotting of PD‐L1 expression in MCUB knockdown (shMCUB) and overexpression (oeMCUB) UMUC3 cells. D) Representative tumor images and tumor weights from xenograft models following MCUB knockdown or overexpression in MB49 cells ( N = 6 per group). E) IHC staining images of PD‐L1 in subcutaneous tumors at 20× and 40× magnifications. Statistical analysis was performed using Student's t ‐test. * p <0.05, ** p <0.01, *** p <0.001.

Journal: Advanced Science

Article Title: MCUB Inhibits PRKN‐Dependent Mitophagic Degradation of PD‐L1 to Promote Immune Evasion in Bladder Cancer

doi: 10.1002/advs.202514764

Figure Lengend Snippet: MCUB promoted PD‐L1 expression and tumor progression in BCa. A) IHC staining images of MCUB and PD‐L1 in 10 BCa samples. B) Correlation analysis between MCUB and PD‐L1 IHC scores. C) Western blotting of PD‐L1 expression in MCUB knockdown (shMCUB) and overexpression (oeMCUB) UMUC3 cells. D) Representative tumor images and tumor weights from xenograft models following MCUB knockdown or overexpression in MB49 cells ( N = 6 per group). E) IHC staining images of PD‐L1 in subcutaneous tumors at 20× and 40× magnifications. Statistical analysis was performed using Student's t ‐test. * p <0.05, ** p <0.01, *** p <0.001.

Article Snippet: MB49 cells (5 × 105 in 100 μL PBS) with stable MCUB knockdown or overexpression were subcutaneously injected into C57BL/6 female mice (6‐8 weeks, n = 6/group, Jackson Laboratory).

Techniques: Expressing, Immunohistochemistry, Western Blot, Knockdown, Over Expression